Baird lowered the firm’s price target on Global Medical REIT (GMRE) to $9 from $10 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which were ahead due to NOI and guidance was unchanged.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMRE:
- Strategic Positioning and Strong Financial Performance Drive Buy Rating for Global Medical REIT
- Cautious Hold Rating on Global Medical REIT Amid Financial Strain and Strategic Uncertainty
- Global Medical REIT reports Q1 AFFO 22c, consensus 22c
- Global Medical REIT backs FY25 AFFO view 89c-93c, consensus 91c
- GMRE Earnings Report this Week: Is It a Buy, Ahead of Earnings?